Access Program Information
A large proportion of Asian patients with HCC present with locally advanced or metastatic
disease,at which point they are ineligible for curative treatments.Oxaliplatin plus
fluorouracil/leucovorin intravenous infusion was proved effective in prolonging
progression-free survival(PFS) than doxorubicin as palliative chemotherapy in patients with
advanced HCC from Asia. Besides, hepatic arterial infusion chemotherapy (HAIC）is a widely
used method for primary or metastasis liver tumor with high local tumor response. To our
knowledge, there have not been any prospective studies to assess the safety and effecacy of
HAIC using oxaliplatin plus fluorouracil/leucovorin for patients with locally advanced
HCC.Thus,the purpose of this phase 2 study was to assess the safety and effecacy of HAIC
using oxaliplatin plus fluorouracil/leucovorin for patients with locally advanced HCC.